Skip to main content

What Incyte's Quarter ended Sep 30, 2026 10-Q says: 2 signals

Incyte filed its latest 10-Q with the SEC on Oct 29, 2026. It discusses acquisition completed and product launch.

Public (INCY)Pharmaceutical Manufacturing5,001 to 10,000 employeesincyte.comLinkedIn

Get Incyte's live signals in Claude or ChatGPT, or by API

AskWhat changed at Incyte this week? Use Autobound signals for incyte.com.
Filed
Oct 29, 2026
Period
Quarter ended Sep 30, 2026
Filings
3
Signals
5

Source: Autobound Signal API · 75 signals tracked for Incyte · updated

10-Q · latest 5

What Incyte's 10-Q filings say

  1. 10-Q · Quarter ended Sep 30, 2026

    Filed · 2 signals

    SEC EDGAR
  2. 10-Q · Quarter ended Jun 30, 2026

    Filed · 2 signals

    SEC EDGAR
  3. 10-Q · Quarter ended Mar 31, 2026

    Filed · 1 signal

    SEC EDGAR

Earnings calls

Incyte earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Total revenue up 14% to $1.56B, net sales reach $1.32BThird quarter total revenue grew 14% year-over-year to $1.56 billion, while total net product sales also rose 14% to $1.32 billion. Growth was led by dermatological asset OPZELURA and the hematology/oncology portfolio, providing financial capacity for commercial expansion and R&D pipelines.
Raised full-year net sales guidance to $5.210B-$5.300BManagement increased full-year 2026 total net sales guidance to $5.210 billion - $5.300 billion on the back of strong nine-month execution. Product line outlooks were also raised, including OPZELURA to $1.100B-$1.120B and hematology/oncology to $890M-$910M, signaling solid commercial budgets through year-end.
Scaling core business beyond Jakafi toward 2029 patent transitionIncyte is executing a strategic portfolio pivot to scale its non-Jakafi core business to $3B-$4B by 2030 to mitigate the upcoming 2029 Jakafi loss of exclusivity. Core business ex-Jakafi delivered $490M in Q3, up 30% YoY, driven by growth in OPZELURA, NIKTIMVO, ZYNYZ, and MONJUVI. Vendors providing clinical development, regulatory affairs, and commercialization services have substantial...
Managing CMS pricing dynamics and Medicaid line extension settlementsIncyte reported net sales growth headwinds driven by expected pricing dynamics, specifically the impact of the CMS GENEROUS Model on Jakafi. Conversely, OPZELURA saw net sales driven by favorable U.S. pricing from a Medicaid line extension agreement with CMS, yielding a pro forma net sales increase of 21% versus unadjusted 36%. Healthcare regulatory compliance, pricing advisory, and...
Collaborating with Tempus for real-world colorectal cancer data analysisIncyte partnered with Tempus to conduct real-world evidence analytics evaluating KRAS-mutant patient outcomes on LONSURF plus bevacizumab to benchmark control expectations for its Phase III DAWN-302 colorectal cancer trial. Life sciences data vendors and analytics platforms can target Incyte's clinical development teams for complementary synthetic control and real-world genomic analytics. The...
Evaluating daraxonrasib post-progression crossover risks in clinical studyIncyte is monitoring post-progression use of competitor therapy daraxonrasib across clinical trial sites for its KRAS G12D inhibitor 734 study. To prevent differential post-progression PFS confounding between treatment arms, management has modeled contingencies to shift enrollment to international countries where daraxonrasib is not commercially approved. CROs and clinical site management...

Signal API · MCP

Track Incyte with the Signal API

One POST /v1/companies/enrich call with incyte.com returns Incyte 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"incyte.com","signal_types":["sec-10q"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.

Talk to sales

Same industry

Questions about Incyte 10-Q

When did Incyte file its latest 10-Q?
Incyte filed its latest 10-Q (Quarter ended Sep 30, 2026) on Oct 29, 2026. The one before it was filed on Jul 28, 2026.
What did Incyte disclose in its latest 10-Q?
From the filing dated Oct 29, 2026: Completed acquisition of Vega Therapeutics Inc. in July 2026
What did Incyte say on its recent earnings calls?
Q3 FY2026: Total revenue up 14% to $1.56B, net sales reach $1.32B (dated Oct 29, 2026).
Where can I read Incyte's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/879169/000087916926000066/incy-20260930.htm. This page summarizes what the filing says and links to it.

Page updated , the date of the newest row on this page.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →